Please check your internet connection and try again.
# Montelukast/Levocetirizine
## Overview
Montelukast/levocetirizine is a fixed-dose combination product used for the treatment of allergic rhinitis. Montelukast is a leukotriene receptor antagonist, and levocetirizine is a second-generation antihistamine.
## Primary Indications
* Allergic rhinitis (seasonal and perennial)
## Adult Dosing
* One tablet (montelukast 10 mg/levocetirizine 5 mg) once daily.
## Pediatric Dosing
* **6 to 14 years:** One tablet (montelukast 4 mg/levocetirizine 2.5 mg - **Note:** This is a separate pediatric product, not a broken adult tablet) once daily.
* Dosing for children under 6 years is not established for this fixed-dose combination. Montelukast and levocetirizine are dosed separately in younger children per their respective product labeling.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required for montelukast. Levocetirizine requires dose adjustment in moderate to severe renal impairment. Since this is a fixed-dose combination, caution and potential dose reduction of the levocetirizine component may be considered, or separate agents may be preferred. Consult product specific information.
* **Hepatic Impairment:** No dose adjustment required for montelukast. Levocetirizine requires dose adjustment in hepatic impairment. Consult product specific information.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, or any component of the formulation.
* Severe renal impairment (for levocetirizine component).
## Adverse Effects
* **Common:** Somnolence, fatigue, dry mouth, pharyngitis, abdominal pain, diarrhea, headache, cough, dizziness, rash.
* **Neuropsychiatric:** Agitation, aggressive behavior, anxiety, depression, hallucinations, insomnia, irritability, suicidal ideation. Montelukast carries a boxed warning regarding neuropsychiatric effects; though rare, these should be monitored.
## Key Drug Interactions
* **Sedatives/CNS Depressants:** Additive sedative effects with levocetirizine (e.g., benzodiazepines, opioids, alcohol).
* **CYP Inhibitors/Inducers:** Montelukast is metabolized by CYP enzymes, but significant interactions are uncommon.
* **Theophylline:** Montelukast may slightly decrease theophylline levels, but clinical significance is usually minimal.
## Monitoring
* Monitor for neuropsychiatric changes (e.g., behavioral changes, mood changes, suicidal thoughts) when initiating and during treatment with montelukast.
* Monitor for somnolence and cognitive impairment, particularly with the levocetirizine component.
* Assess for effectiveness in symptom control of allergic rhinitis.
## Clinical Pearls
* This combination is for patients who require treatment for both asthma and allergic rhinitis, or where symptom control of allergic rhinitis is not adequately achieved with a single agent.
* Montelukast should not be used to treat acute asthma attacks.
* Levocetirizine can cause drowsiness; advise patients to use caution when driving or operating machinery.
* For patients with significant renal impairment, consider using separate montelukast and levocetirizine formulations to allow for appropriate dose adjustment of levocetirizine.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature before making clinical decisions. Product availability and specific formulations may vary by region.*
